|
Experts called for more transparency in vaccine supervision after China's drug regulator disclosed last Tuesday that it had denied market access for more than 100,000 doses of rabies vaccine produced by two manufacturers in Jilin province. 在中国药品监管机构上周二披露吉林省两家制造商生产的10万多剂狂犬病疫苗被拒绝进入市场后，专家们发出了提高疫苗监管透明度的呼吁。 Some 43,510 doses from Maifeng Bio Tech Co failed premarket checks of safety and effectiveness on Oct 29, as did 57,290 doses from Zhuoyi Biological Co on Nov 5. Both manufacturers are based in Changchun, Jilin. 10月29日，迈丰生物药业有限公司约43510剂疫苗未能通过上市前的安全性和有效性检测，11月5日，卓谊生物股份有限公司的57290剂疫苗也未能通过检测。两家制造商都位于吉林长春。 | 
